STX-478

CAS No. 2883540-92-7

STX-478( —— )

Catalog No. M37154 CAS No. 2883540-92-7

STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 206 In Stock
5MG 187 In Stock
10MG 302 In Stock
25MG 541 In Stock
50MG 797 In Stock
100MG 1190 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    STX-478
  • Note
    Research use only, not for human use.
  • Brief Description
    STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.
  • Description
    STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research.
  • In Vitro
    Immunofluorescence Cell Line:MCF10A cells Concentration:0-10,000 nM Incubation Time:1 h Result:Targeted the MCF10A cells (with the H1047R kinase domain mutation).
  • In Vivo
    Animal Model:Female BALB/c nude mice (CAL-33 xenograft model).Dosage:30, 100 mg/kg Administration:Oral administration Result:Showed a dose-dependent reduction in tumor volume.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2883540-92-7
  • Formula Weight
    401.29
  • Molecular Formula
    C16H12F5N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (622.99 mM; Ultrasonic )
  • SMILES
    [C@H](NC(NC=1C=NC(N)=NC1)=O)(C(F)(F)F)C2=C(C)C=3C(O2)=C(F)C=C(F)C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1.
molnova catalog
related products
  • CYH33 methanesulfona...

    CYH33 (CYH-33) is a novel potent, PI3Kα-selective inhibitor with IC50 of 5.9 nM/598 nM/ 78.7 nM/225 nM aginst class I PI3K isoform α/β/δ/γ, respectively.

  • PI3Kδ inhibitor 52

    A potent, selective, and efficacious PI3Kδ inhibitor with IC50 of 1.7 nM.

  • PI3Kα-IN-243

    A potent PI3Kα inhibitor with IC50 of <0.1 uM; also inhibits HDAC (IC50=0.1-1 uM).